December 17, 2010 – An ultrasound contrast agent is under review by the U.S. Food and Drug Administration (FDA) for use in stress echocardiography. Lantheus Medical Imaging recently submitted a supplemental new drug application for its Definity (Perflutren Lipid Microsphere) Injectable Suspension.
December 17, 2010 - The U.S. Food and Drug Administration (FDA) has requested additional analyses of the trial data in its review of the new antiplatelet agent ticagrelor (Brilinta).
December 17, 2010 – The first truly detachable hydrogel polymer embolic device is now available nationwide. The AZUR Peripheral HydroCoil 35 platinum coil embolization system, from Terumo Interventional Systems, is designed for treating high-flow and challenging blood vessels, vascular malformations and aneurysms.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
December 16, 2010 – Bracco Imaging demonstrated how its customized evidence-based diagnostic imaging solutions are meeting the demands of an evolving radiology market at the Radiological Society of North America (RSNA) meeting.
December 16, 2010 – An upgraded remote ECG viewing system is now live across the United States, United Kingdom and Canada and is available for immediate download to customers in those countries.
December 16, 2010 – The "2010 Top 20 Best in KLAS Awards: Software & Professional Services" report from KLAS has been released. The report includes the annual rankings of the best-performing healthcare IT vendors based on more than 17,000 interviews conducted yearly with healthcare providers.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
December 16, 2010 – A system designed to improve acute coronary syndrome (ACS) revascularization following percutaneous coronary intervention (PCI) has received CE Mark.
December 15, 2010 – When physicians who are not radiologists refer patients to imaging facilities they own or lease, their patients don’t always benefit, according to a series of studies in Health Affairs.
December 15, 2010 – A guest editorial in the new publication Clinical Investigation highlights dabigatran etexilate as an alternative to warfarin for long-term stroke prevention in patients with non-valvular atrial fibrillation.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 13, 2010 – Two echocardiographs (ECGs) that deliver built-in, bi-directional communication to help customers connect to electronic medical records (EMRs) have been added. The two new ECGs, under Cardiac Science’s Burdick brand, are only available in the United States.
December 13, 2010 – Based on emerging safety information, the pulmonary arterial hypertension (PAH) drug sitaxentan is being voluntarily withdrawn from the market. Pfizer is also discontinuing studies involving sitaxentan (Thelin) worldwide,
December 13, 2010 - One possible explanation for disparities in care for acute coronary syndrome between men and women may be that women are less likely to accept their physician’s recommendation on treatment. The results of the study were reported online today in Annals of Emergency Medicine.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Aortic stenosis (AS) is one of the most common valvular disorders in older adults, with a prevalence of approximately 8 percent at age 85 (1).
There have only been incremental improvements in intravascular ultrasound (IVUS) over the past decade. However, three new technologies introduced in 2010, and a few more expected to enter trials or be commercialized in 2011, are pushing new frontiers. Characterizing Plaque
During a time when the U.S. healthcare reform is on the minds of many within the medical community, physicians and hospital administrators are continuously looking for ways to cut spending. One avenue that physicians and hospitals are exploring is to limit the use of expensive medical devices, such as drug-eluting stents (DES).